Fig. 2From: SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observationSubgroup analyses of overall survival. HR, hazard ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; D-SOX, intraperitoneal docetaxel and intravenous oxaliplatin plus taking orally S-1; DOS, intravenous docetaxel and oxaliplatin plus taking orally S-1Back to article page